Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other financing activities (2016 - 2025)

Historic Other financing activities for United Therapeutics (UTHR) over the last 16 years, with Q2 2025 value amounting to $11.5 million.

  • United Therapeutics' Other financing activities changed N/A to $11.5 million in Q2 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 32592.59%. This contributed to the annual value of $2.7 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that United Therapeutics reported Other financing activities of $11.5 million as of Q2 2025.
  • In the past 5 years, United Therapeutics' Other financing activities registered a high of $11.5 million during Q2 2025, and its lowest value of $2.7 million during Q1 2023.
  • Its 4-year average for Other financing activities is $6.1 million, with a median of $5.1 million in 2022.
  • As far as peak fluctuations go, United Therapeutics' Other financing activities tumbled by 6400.0% in 2023, and later changed by 0.0% in 2024.
  • Over the past 4 years, United Therapeutics' Other financing activities (Quarter) stood at $7.5 million in 2022, then tumbled by 64.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then soared by 325.93% to $11.5 million in 2025.
  • Its Other financing activities stands at $11.5 million for Q2 2025, versus $2.7 million for Q1 2024 and $2.7 million for Q1 2023.